Educating Pharmacists on New Treatments for Osteoarthritis Pain

Contact: Matt Miller
Phone: 646-336-6495
Fax: 646-336-6497
Email: [email protected]

NEW YORK (9/15/2021) – DKBmed, LLC has developed a webcast to educate clinicians on current and emerging strategies to limit pain in patients diagnosed with osteoarthritis. The program, entitled Optimizing Pain Management: Osteoarthritis Education for Pharmacists, will features expert faculty lectures and visual data aids to enhance the learning experience.

Osteoarthritis (OA) is a major public health challenge and affects approximately 10.5% of adults in the United States. Patients with an OA diagnosis experience cartilaginous degeneration and joint space narrowing, which can lead to pain and progressive disability. Functional limitations, which are twice as common among patients with OA than in the general population, lead to staggering costs at the individual and societal level. Despite these costs, management options for OA have stagnated in recent years and available agents offer limited clinical benefit. Consequently, many patients with OA have inadequate treatment options and a dire need for more effective alternatives. One such option may be nerve growth factor (NGF) inhibitors, which have emerged in recent years as a compelling option for clinicians seeking to control osteoarthritic pain.

“Medications that block NGF may reduce or eliminate the need for certain pain-relieving medications, namely opioids,” notes Robert L, Barkin, MBA, PharmD, FPC from Rush Medical School of Rush University. “Pharmacists who encounter patients with chronic pain and those developing formularies need to understand the role of NGF.”

Optimizing Pain Management: Osteoarthritis Education for Pharmacists will offer an immersive audiovisual experience and feature 2D and 3D animations illustrating how NGF-sequestering agents mediate pain in patients with OA. The webcast will also examine other pertinent topics for pharmacists, including:

The social and personal challenges associated with OA, including differences in patient burden and disease severity across racial and gender lines
The relationship and impact of comorbidities on OA
Limitations of current nonpharmacologic and pharmacologic treatments

About DKBmed

DKBmed is an integrated continuing medical education company operated by an experienced team of medical education experts. DKBmed provides health care professionals with effective medical education that closes identified knowledge and practice gaps to improve patient health.

Working with accredited providers and other partners, DKBmed develops innovative educational programs and quality improvement (QI) initiatives, bringing new learning methodologies to the CME landscape. DKBmed has become a leader in QI in the independent medical education space with QI projects in Pain Management, HIV, Depression, Influenza, and Diabetic Eye Disease. DKBmed was also an early adopter of case scenarios with real patients and live actors, TED/DKBmed Talks, 3D animation, webcasts, podcasts, and smart phone applications for clinicians and patients. These forward-thinking approaches enable health care professionals to learn and access educational programs in a manner that is most convenient and appropriate for them.

DKBmed’s programs are accessible through the company’s website (www.dkbmed.com). They reach more than 150,000 health care professionals in primary care and in a variety of specialties and disease states including: HIV, COVID-19, cystic fibrosis, diabetes, influenza, dermatology, retinal disease, rheumatoid arthritis, COPD, asthma, multiple sclerosis, pain management, depression and viral hepatitis (HBV, HCV) and oncology.